Connect with us

Technology

Unisys Announces 3Q24 Results

Published

on

Unisys Continues Strong New Business(6) Signings and Raises Profitability Guidance

 Revenue growth of 7.0% year over year (YoY), an 8.2% increase in constant currency(1) Gross profit margin of 29.2%, up 870 bps YoY; Excluding License and Support (Ex-L&S)(15) gross profit margin of 17.9%, up 390 bps YoYOperating profit margin of 1.5 %, up 520 bps YoY; non-GAAP operating profit(8) margin of 9.9 %, up 980 bps YoYCash provided by operations of $32.0 million, compared to cash used for operations of $(4.1) million for the third quarter of 2023 (3Q23), and free cash flow(11) of $14.2 million compared to $(25.7) million for 3Q23New Business Total Contract Value (TCV)(4) increased 50% YoY driven by more than doubling of new logo signingsUnisys raises 2024 non-GAAP operating profit margin guidance from 5.5% to 7.5% to 6.5% to 8.5%

BLUE BELL, Pa., Oct. 29, 2024 /PRNewswire/ — Unisys Corporation (NYSE: UIS) reported financial results for the third quarter of 2024 (3Q24).

“Our strong year-over-year growth in New Business signings continues to demonstrate increased awareness and demand for Unisys’ solutions,” said Unisys Chair and CEO Peter A. Altabef. “We have experienced substantial growth in our AI solutions in production and are strengthening engagement with clients on their AI strategies and projects. We are also pleased with the strong sequential growth in our pipeline.”

Unisys Chief Financial Officer Deb McCann said, “We are reiterating full-year revenue guidance and raising our full-year profitability guidance and expectation for cash generation. We continued to drive year-over-year profitability improvement, including in our Ex-L&S solutions, reflecting the progress we are making with our delivery and operational efficiency initiatives. Also, we strengthened our liquidity position with cash balances increasing sequentially to $374 million and obtaining an extension of our ABL credit facility through October 2027.”

Financial Highlights

Please refer to the accompanying financial tables for a reconciliation of the GAAP to non-GAAP measures presented except for financial guidance since such a reconciliation is not practicable without unreasonable effort.

(In millions, except numbers presented as percentages)

3Q24

3Q23

YTD24

YTD23

Revenue

$497.0

$464.6

$1,463.0

$1,457.8

YoY revenue growth

7.0 %

0.4 %

YoY revenue growth in constant currency

8.2 %

0.2 %

Ex-L&S revenue

$392.5

$397.5

$1,183.2

$1,173.0

YoY revenue growth

(1.3) %

0.9 %

YoY revenue growth in constant currency

(0.1) %

1.0 %

License and Support(14) revenue

$104.5

$67.1

$279.8

$284.8

YoY revenue growth

55.7 %

(1.8) %

YoY revenue growth in constant currency

57.3 %

(3.0) %

Gross profit

$145.0

$95.3

$410.9

$370.1

Gross profit percent

29.2 %

20.5 %

28.1 %

25.4 %

Ex-L&S gross profit

$70.3

$55.7

$215.7

$171.6

Ex-L&S gross profit percent

17.9 %

14.0 %

18.2 %

14.6 %

Operating profit (loss)

$7.5

($17.1)

$48.8

$32.9

Operating profit (loss) percent

1.5 %

(3.7) %

3.3 %

2.3 %

Non-GAAP operating profit

$49.4

$0.4

$113.1

$76.8

Non-GAAP operating profit percent

9.9 %

0.1 %

7.7 %

5.3 %

Net loss attributable to Unisys Corporation

($61.9)

($50.0)

($223.4)

($265.4)

Non-GAAP net income (loss) attributable to Unisys Corporation(10)

($5.8)

($22.3)

$7.9

$6.3

EBITDA(9)

$18.1

$7.6

($50.4)

($100.9)

Adjusted EBITDA(9)

$77.0

$37.0

$200.7

$185.5

Adjusted EBITDA as a percentage of revenue

15.5 %

8.0 %

13.7 %

12.7 %

Third Quarter 2024 Results

Revenue growth of 7.0% YoY, an 8.2% increase in constant currency, primarily driven by the timing of software license renewals. Ex-L&S revenue declined 1.3% YoY, a 0.1% decrease in constant currency.

Gross profit margin improved 870 bps YoY primarily driven by the timing of software license renewals. Ex-L&S gross profit margin improved 390 bps YoY primarily driven by delivery improvements and labor cost savings initiatives. Additionally, prior year Ex-L&S gross profit margin was negatively impacted by certain adjustments related to a previously exited contract.

Operating profit margin improved 520 bps YoY primarily driven by higher gross profit margin and lower professional services expense, partially offset by a non-cash goodwill impairment charge of $39.1 million related to the Digital Workplace Solutions segment.

Net loss attributable to Unisys Corporation included an additional $29.0 million tax accrual established for certain foreign subsidiaries for which the company is no longer asserting indefinite reinvestment of earnings.

Financial Highlights by Segment

(In millions, except numbers presented as percentages)

3Q24

3Q23

YTD24

YTD23

Digital Workplace Solutions (DWS):

Revenue

$130.9

$140.9

$395.3

$406.9

YoY revenue growth

(7.1) %

(2.9) %

YoY revenue growth in constant currency

(6.2) %

(2.8) %

Gross profit

$21.3

$20.9

$61.7

$54.9

Gross profit percent

16.3 %

14.8 %

15.6 %

13.5 %

Cloud, Applications & Infrastructure Solutions (CA&I):

Revenue

$131.5

$133.5

$394.8

$392.1

YoY revenue growth

(1.5) %

0.7 %

YoY revenue growth in constant currency

(1.3) %

0.7 %

Gross profit

$21.5

$20.4

$66.8

$59.2

Gross profit percent

16.3 %

15.3 %

16.9 %

15.1 %

Enterprise Computing Solutions (ECS):

Revenue

$157.9

$122.2

$442.4

$445.0

YoY revenue growth

29.2 %

(0.6) %

YoY revenue growth in constant currency

32.7 %

(0.9) %

Gross profit

$94.8

$61.4

$256.7

$259.7

Gross profit percent

60.0 %

50.2 %

58.0 %

58.4 %

Third Quarter 2024 Segment Results

DWS revenue declined 7.1% YoY, a decline of 6.2% in constant currency, primarily driven by lower discretionary volume with clients. DWS gross profit margin was 16.3%, an increase of 150 bps YoY, reflecting results from delivery modernization and efficiency initiatives.

CA&I revenue declined 1.5% YoY, a decline of 1.3% in constant currency. CA&I gross profit margin was 16.3%, an increase of 100 bps YoY, primarily driven by labor cost savings initiatives.

ECS revenue increased 29.2% YoY, an increase of 32.7% in constant currency. ECS gross profit margin was 60.0%, an increase of 980 bps YoY. The increase in revenue and gross profit margin was primarily driven by the timing of software license renewals.

Balance Sheet and Cash Flows

(In millions)

September 30,
2024

December 31,
2023

Cash and cash equivalents

$               373.7

$               387.7

 

(In millions)

3Q24

3Q23

YTD24

YTD23

Cash provided by (used for) operations

$32.0

($4.1)

$58.5

$51.2

Free cash flow

$14.2

($25.7)

($0.4)

($8.5)

Pre-pension and postretirement free cash flow(12)

$22.8

($15.5)

$20.6

$32.8

Adjusted free cash flow(13)

$28.3

$1.4

$37.5

$89.5

Other Key Performance Metrics

YoY
Change

QoQ
Change*

TCV

Total company

36 %

(22) %

Ex-L&STCV

18 %

(25) %

Pipeline(3)

Total company

(13) %

9 %

Ex-L&S pipeline

(12) %

10 %

*    QoQ – quarter over quarter

TCV improvement YoY was primarily due to increased New Business TCV of 50% YoY, primarily driven by new logo signings more than doubling YoY.

Total company and Ex-L&S pipeline declines YoY resulted from strong New Business conversion and timing of the Ex-L&S renewal schedule.

Backlog(2) was $2.80 billion for the third quarter of 2024 compared to $2.38 billion for the third quarter of 2023.

2024 Financial Guidance

The company reiterates full-year 2024 revenue growth and raises profitability guidance:

 Guidance

Revenue growth in constant currency

(1.5)% to 1.5%

Revised non-GAAP operating profit margin*

6.5% to 8.5%

*    Prior issued guidance for profitability was 5.5% to 7.5%.

Constant currency revenue guidance translates to reported revenue growth of (1.0)% to 2.0%, based on recent exchange rates, and assumes L&S revenue of approximately $415 million and Ex-L&S revenue growth near the low end of 1.5% to 5.0%.

Conference Call

Unisys will hold a conference call with the financial community on Wednesday, October 30 at 8 a.m. Eastern Time to discuss the results of the third quarter of 2024.

The live, listen-only webcast, as well as the accompanying presentation materials, can be accessed on the Unisys Investor Website at www.unisys.com/investor. In addition, domestic callers can dial 1-844-695-5518 and international callers can dial 1-412-902-6749 and provide the following conference passcode: Unisys Corporation Call.

A webcast replay will be available on the Unisys Investor Website shortly following the conference call. A replay will also be available by dialing 1-877-344-7529 for domestic callers or 1-412-317-0088 for international callers and entering access code 8177230 from two hours after the end of the call until November 13, 2024.

(1) Constant currency – A significant amount of the company’s revenue is derived from international operations. As a result, the company’s revenue has been and will continue to be affected by changes in the U.S. dollar against major international currencies. The company refers to revenue growth rates in constant currency or on a constant currency basis so that the business results can be viewed without the impact of fluctuations in foreign currency exchange rates to facilitate comparisons of the company’s business performance from one period to another. Constant currency is calculated by retranslating current and prior-period revenue at a consistent exchange rate rather than the actual exchange rates in effect during the respective periods.

(2) Backlog – Represents future revenue associated with contracted work, which has not yet been delivered or performed. Although the company believes this revenue will be recognized, it may, for commercial reasons, allow the orders to be canceled, with or without penalty.

(3) Pipeline – Represents qualified prospective sale opportunities for which bids have been submitted or vetted prospective sales opportunities which are being actively pursued. There is no assurance that pipeline will translate into recorded revenue.

(4) Total Contract Value (TCV) – Represents the estimated revenue related to contracts signed in the period without regard for cancellation terms. New Business TCV represents TCV attributable to expansion and new scope for existing clients and new logo contracts.

(5) Book-to-bill – Represents total contract value booked divided by revenue in a given period.

(6) New Business – Represents expansion and new scope for existing clients and new logo contracts.

(7) Next-Gen Solutions – Includes our Modern Workplace solutions within DWS, Digital Platforms and Applications (DP&A) solutions within CA&I, Specialized Services and Next-Gen Compute (SS&C) solutions within ECS, as well as Micro-Market solutions. The company uses estimated Next-Gen Solutions metrics to provide insight into the company’s progress in shifting the revenue mix towards solutions that are generally higher-growth and higher-margin.

(8) Non-GAAP operating profit – This measure excludes pretax pension and postretirement expense, pretax goodwill impairment charge and pretax charges in connection with certain legal matters related to professional services and legal fees, including legal defense costs, associated with certain legal proceedings, and cost-reduction activities and other expenses.

(9) EBITDA & adjusted EBITDA – Earnings before interest, taxes, depreciation and amortization (EBITDA) is calculated by starting with net income (loss) attributable to Unisys Corporation common shareholders and adding or subtracting the following items: net income (loss) attributable to noncontrolling interests, interest expense (net of interest income), provision for (benefit from) income taxes, depreciation and amortization. Adjusted EBITDA further excludes pension and postretirement expense; goodwill impairment charge; certain legal matters related to settlements, professional services and legal fees, including legal defense costs, associated with certain legal proceedings; environmental matters related to previously disposed businesses; cost-reduction activities and other expenses, non-cash share-based expense, and other (income) expense adjustments.

(10) Non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share – These measures excluded pension and postretirement expense, and charges or (credits) in connection with goodwill impairment; certain legal matters related to settlements, professional services and legal fees, including legal defense costs, associated with certain legal proceedings; environmental matters related to previously disposed businesses; cost-reduction activities and other expenses. The tax amounts related to these items for the calculation of non-GAAP diluted earnings (loss) per share include the current and deferred tax expense and benefits recognized under GAAP for these items.

(11) Free cash flow – Represents cash flow from operations less capital expenditures.

(12) Pre-pension and postretirement free cash flow – Represents free cash flow before pension and postretirement contributions.

(13) Adjusted free cash flow – Represents free cash flow less cash used for pension and postretirement funding; certain legal matters related to professional services and legal fees, including legal defense costs, associated with certain legal proceedings; environmental matters related to previously disposed businesses; and cost-reduction activities and other payments.

(14) License and Support (L&S) – Represents software license and related support revenue within the company’s ECS segment.

(15) Excluding License and Support (Ex-L&S) – These measures exclude revenue, gross profit and gross profit margin in connection with software license and support revenue within the company’s ECS segment. The company provides these measures to allow investors to isolate the impact of software license renewals, which tend to be significant and impactful based on timing, and related support services in order to evaluate the company’s business outside of these areas.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Unisys cautions readers that the assumptions forming the basis for forward-looking statements include many factors that are beyond Unisys’ ability to control or estimate precisely, such as estimates of future market conditions, the behavior of other market participants and that TCV is based, in part, on the assumption that each of those contracts will continue for their full contracted term. Words such as “anticipates,” “estimates,” “expects,” “projects,” “may,” “will,” “intends,” “plans,” “believes,” “should” and similar expressions may identify forward-looking statements and such forward-looking statements are made based upon management’s current expectations, assumptions and beliefs as of this date concerning future developments and their potential effect upon Unisys. There can be no assurance that future developments will be in accordance with management’s expectations, assumptions and beliefs or that the effect of future developments on Unisys will be those anticipated by management. Forward-looking statements in this release and the accompanying presentation include, but are not limited to, statements made in Mr. Altabef’s and Ms. McCann’s quotations, any projections or expectations of revenue growth, margin expansion, achievement of operational efficiencies and savings, investments in artificial intelligence adoption and innovation, future growth of our Next-Gen Solutions(7), TCV and New Business TCV, the impact of New Logo signings, the impact of Unisys Logistics Optimization, backlog, pipeline, book-to-bill(5), full-year 2024 revenue growth and profitability guidance, including constant currency revenue, Ex-L&S revenue growth, L&S revenue, non-GAAP operating profit margin, free cash flow generation and the assumptions and other expectations made in connection with our full-year 2024 financial guidance, our pension liability, future economic benefits from net operating losses and statements regarding future economic conditions or performance. 

Additional information and factors that could cause actual results to differ materially from Unisys’ expectations are contained in Unisys’ filings with the U.S. Securities and Exchange Commission (SEC), including Unisys’ Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K, and other SEC filings, which are available at the SEC’s web site, http://www.sec.gov. Information included in this release is representative as of the date of this release only and while Unisys periodically reassesses material trends and uncertainties affecting Unisys’ results of operations and financial condition in connection with its preparation of management’s discussion and analysis of results of operations and financial condition contained in its Quarterly and Annual Reports filed with the SEC, Unisys does not, by including this statement, assume any obligation to review or revise any particular forward-looking statement referenced herein in light of future events.

Non-GAAP Information

This release includes certain non-GAAP financial measures that exclude certain items such as postretirement expense; certain legal and other matters related to professional services and legal fees, including legal defense costs, associated with certain legal proceedings; environmental matters related to previously disposed businesses; and cost-reduction activities and other expenses that the company believes are not indicative of its ongoing operations, as they may be unusual or non-recurring. The inclusion of such items in financial measures can make the company’s profitability and liquidity results difficult to compare to prior periods or anticipated future periods and can distort the visibility of trends associated with the company’s ongoing performance. Management also believes that non-GAAP measures are useful to investors because they provide supplemental information about the company’s financial performance and liquidity, as well as greater transparency into management’s view and assessment of the company’s ongoing operating performance.

Non-GAAP financial measures are often provided and utilized by the company’s management, analysts, and investors to enhance comparability of year-over-year results and to isolate in some instances the impact of software license renewals, which tend to be lumpy, and related support services in order to evaluate the company’s business outside of these areas. These items are uncertain, depend on various factors, and could have a material impact on the company’s GAAP results for the applicable period. These measures should not be relied upon as substitutes for, or considered in isolation from, measures calculated in accordance with U.S. GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found below except for financial guidance and other forward-looking information since such a reconciliation is not practicable without unreasonable efforts as the company is unable to reasonably forecast certain amounts that are necessary for such reconciliation. This information has been provided pursuant to the requirements of SEC Regulation G.

About Unisys

Unisys is a global technology solutions company that powers breakthroughs for the world’s leading organizations. Our solutions – cloud, AI, digital workplace, logistics and enterprise computing – help our clients challenge the status quo and unlock their full potential. To learn how we have been helping clients push what’s possible for more than 150 years, visit unisys.com and follow us on LinkedIn.

RELEASE NO.: 1029/9967

Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.

UIS-Q

 

UNISYS CORPORATION

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Unaudited)

(Millions, except per share data)

Three Months Ended

September 30,

Nine Months Ended

September 30,

2024

2023

2024

2023

Revenue

Services

$        414.9

$        415.2

$    1,247.8

$    1,236.1

Technology

82.1

49.4

215.2

221.7

497.0

464.6

1,463.0

1,457.8

Costs and expenses

Cost of revenue

Services

308.9

324.0

935.9

963.6

Technology

43.1

45.3

116.2

124.1

352.0

369.3

1,052.1

1,087.7

Selling, general and administrative

91.9

108.1

305.5

321.3

Research and development

6.5

4.3

17.5

15.9

Goodwill impairment

39.1

—

39.1

—

489.5

481.7

1,414.2

1,424.9

Operating income (loss)

7.5

(17.1)

48.8

32.9

Interest expense

7.9

7.8

23.7

22.9

Other (expense), net

(8.2)

(3.6)

(159.7)

(217.2)

Loss before income taxes

(8.6)

(28.5)

(134.6)

(207.2)

Provision for income taxes

53.3

20.4

89.1

55.7

Consolidated net loss

(61.9)

(48.9)

(223.7)

(262.9)

Net income (loss) attributable to noncontrolling interests

—

1.1

(0.3)

2.5

Net loss attributable to Unisys Corporation

$        (61.9)

$        (50.0)

$      (223.4)

$      (265.4)

Loss per share attributable to Unisys Corporation

Basic

$        (0.89)

$        (0.73)

$        (3.23)

$        (3.89)

Diluted

$        (0.89)

$        (0.73)

$        (3.23)

$        (3.89)

 

UNISYS CORPORATION

SEGMENT RESULTS

(Unaudited)

(Millions)

Total

DWS

CA&I

ECS

Other

Three Months Ended September 30, 2024

Revenue

$        497.0

$        130.9

$        131.5

$        157.9

$              76.7

Gross profit percent

29.2 %

16.3 %

16.3 %

60.0 %

Three Months Ended September 30, 2023

Revenue

$        464.6

$        140.9

$        133.5

$        122.2

$              68.0

Gross profit percent

20.5 %

14.8 %

15.3 %

50.2 %

Total

DWS

CA&I

ECS

Other

Nine Months Ended September 30, 2024

Revenue

$    1,463.0

$        395.3

$        394.8

$        442.4

$           230.5

Gross profit percent

28.1 %

15.6 %

16.9 %

58.0 %

Nine Months Ended September 30, 2023

Revenue

$    1,457.8

$        406.9

$        392.1

$        445.0

$           213.8

Gross profit percent

25.4 %

13.5 %

15.1 %

58.4 %

 

UNISYS CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(Millions)

September 30,
2024

December 31,
2023

Assets

Current assets:

Cash and cash equivalents

$               373.7

$                  387.7

Accounts receivable, net

447.0

454.5

Contract assets

13.2

11.7

Inventories

20.1

15.3

Prepaid expenses and other current assets

93.1

101.8

Total current assets

947.1

971.0

Properties

400.8

396.4

Less-accumulated depreciation and amortization

342.7

332.1

Properties, net

58.1

64.3

Outsourcing assets, net

24.6

31.6

Marketable software, net

170.2

166.2

Operating lease right-of-use assets

40.0

35.4

Prepaid pension and postretirement assets

44.2

38.0

Deferred income taxes

107.2

114.0

Goodwill

248.5

287.4

Intangible assets, net

36.6

42.7

Restricted cash

8.0

9.0

Assets held-for-sale

4.9

4.9

Other long-term assets

172.2

200.9

Total assets

$            1,861.6

$               1,965.4

Total liabilities and deficit

Current liabilities:

Current maturities of long-term debt

$                   7.7

$                    13.0

Accounts payable

119.9

130.9

Deferred revenue

185.0

198.6

Other accrued liabilities

272.7

308.4

Total current liabilities

585.3

650.9

Long-term debt

488.5

491.2

Long-term pension and postretirement liabilities

771.0

787.7

Long-term deferred revenue

106.3

104.4

Long-term operating lease liabilities

29.4

25.6

Other long-term liabilities

69.0

44.0

Commitments and contingencies

Total Unisys Corporation stockholders’ deficit

(202.2)

(151.8)

Noncontrolling interests

14.3

13.4

Total deficit

(187.9)

(138.4)

Total liabilities and deficit

$            1,861.6

$               1,965.4

 

UNISYS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Millions)

Nine Months Ended

September 30,

2024

2023

Cash flows from operating activities

Consolidated net loss

$       (223.7)

$       (262.9)

Adjustments to reconcile consolidated net loss to net cash provided by operating activities:

Foreign currency losses (gains)

10.5

(2.1)

Non-cash interest expense

0.9

0.9

Employee stock compensation

16.2

12.9

Depreciation and amortization of properties

18.0

20.9

Depreciation and amortization of outsourcing assets

18.0

37.5

Amortization of marketable software

35.7

37.7

Amortization of intangible assets

6.1

7.3

Goodwill impairment

39.1

—

Other non-cash operating activities

(0.7)

0.4

Loss on disposal of capital assets

0.1

0.3

Pension and postretirement contributions

(21.0)

(41.3)

Pension and postretirement expense

171.1

214.1

Deferred income taxes, net

33.5

14.5

Changes in operating assets and liabilities, excluding the effect of acquisitions:

Receivables, net and contract assets

27.9

58.3

Inventories

(4.9)

(0.6)

Other assets

(3.5)

(24.8)

Accounts payable and current liabilities

(76.2)

(33.7)

Other liabilities

11.4

11.8

Net cash provided by operating activities

58.5

51.2

Cash flows from investing activities

Proceeds from foreign exchange forward contracts

2,285.1

2,044.3

Purchases of foreign exchange forward contracts

(2,279.9)

(2,030.0)

Investment in marketable software

(36.7)

(32.9)

Capital additions of properties

(11.0)

(15.4)

Capital additions of outsourcing assets

(11.2)

(11.4)

Other

(0.3)

(0.9)

Net cash used for investing activities

(54.0)

(46.3)

Cash flows from financing activities

Payments of long-term debt

(11.8)

(13.7)

Other

(1.9)

(0.4)

Net cash used for financing activities

(13.7)

(14.1)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(5.8)

0.4

Decrease in cash, cash equivalents and restricted cash

(15.0)

(8.8)

Cash, cash equivalents and restricted cash, beginning of period

396.7

402.7

Cash, cash equivalents and restricted cash, end of period

$         381.7

$         393.9

 

UNISYS CORPORATION

RECONCILIATIONS OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES

(Unaudited)

(Millions, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

Net loss attributable to Unisys Corporation

$        (61.9)

$        (50.0)

$      (223.4)

$      (265.4)

Pension and postretirement expense

pretax

12.1

10.3

171.1

214.1

tax

0.2

(0.2)

0.4

(0.6)

net of tax

11.9

10.5

170.7

214.7

Goodwill impairment

pretax

39.1

—

39.1

—

tax

—

—

—

—

net of tax

39.1

—

39.1

—

Certain legal matters

pretax

0.8

9.4

(0.9)

23.8

tax

—

—

(2.8)

—

net of tax

0.8

9.4

1.9

23.8

Environmental matters

pretax

0.4

(0.1)

1.4

17.7

tax

—

—

—

—

net of tax

0.4

(0.1)

1.4

17.7

Cost reduction and other expenses

pretax

3.9

8.3

18.5

16.2

tax

—

0.4

0.3

0.7

net of tax

3.9

7.9

18.2

15.5

Non-GAAP net (loss) income attributable to Unisys Corporation

$          (5.8)

$        (22.3)

$            7.9

$            6.3

Weighted average shares (thousands)

69,357

68,381

69,112

68,205

Plus incremental shares from assumed vesting:

Employee stock plans

—

—

—

—

Adjusted weighted average shares

69,357

68,381

69,112

68,205

Weighted average shares (thousands)

69,357

68,381

69,112

68,205

Plus incremental shares from assumed vesting:

Employee stock plans

—

—

1,960

805

Non-GAAP adjusted weighted average shares

69,357

68,381

71,072

69,010

Diluted loss per share

Net loss attributable to Unisys Corporation

$        (61.9)

$        (50.0)

$      (223.4)

$      (265.4)

Divided by adjusted weighted average shares

69,357

68,381

69,112

68,205

Diluted loss per share

$        (0.89)

$        (0.73)

$        (3.23)

$        (3.89)

Non-GAAP basis

Non-GAAP net (loss) income attributable to Unisys Corporation for diluted (loss) earnings per share

$          (5.8)

$        (22.3)

$            7.9

$            6.3

Divided by Non-GAAP adjusted weighted average shares

69,357

68,381

71,072

69,010

Non-GAAP diluted (loss) earnings per share

$        (0.08)

$        (0.33)

$          0.11

$          0.09

 

UNISYS CORPORATION

RECONCILIATIONS OF GAAP TO NON-GAAP

 (Unaudited)

(Millions)

FREE CASH FLOW

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

Cash provided by (used for) operations

$          32.0

$          (4.1)

$          58.5

$          51.2

Additions to marketable software

(11.0)

(11.6)

(36.7)

(32.9)

Additions to properties

(3.7)

(3.5)

(11.0)

(15.4)

Additions to outsourcing assets

(3.1)

(6.5)

(11.2)

(11.4)

Free cash flow

14.2

(25.7)

(0.4)

(8.5)

Pension and postretirement funding

8.6

10.2

21.0

41.3

Pre-pension and postretirement free cash flow

22.8

(15.5)

20.6

32.8

Certain legal payments

(0.5)

7.4

2.0

20.4

Environmental matters payments

4.0

3.8

8.4

14.5

Cost reduction and other payments, net

2.0

5.7

6.5

21.8

Adjusted free cash flow

$          28.3

$            1.4

$          37.5

$          89.5

 

UNISYS CORPORATION

RECONCILIATIONS OF GAAP TO NON-GAAP

 (Unaudited)

(Millions)

EBITDA

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

Net loss attributable to Unisys Corporation

$        (61.9)

$        (50.0)

$      (223.4)

$      (265.4)

Net income (loss) attributable to noncontrolling interests

—

1.1

(0.3)

2.5

Interest expense, net of interest income of $5.5, $6.9, $17.3 and $20.0, respectively(1)

2.4

0.9

6.4

2.9

Provision for income taxes

53.3

20.4

89.1

55.7

Depreciation

11.3

19.6

36.0

58.4

Amortization

13.0

15.6

41.8

45.0

EBITDA

$          18.1

$            7.6

$        (50.4)

$      (100.9)

Pension and postretirement expense

$          12.1

$          10.3

$        171.1

$        214.1

Goodwill impairment

39.1

—

39.1

—

Certain legal matters(2)

0.8

9.4

(0.9)

23.8

Environmental matters(1)

0.4

(0.1)

1.4

17.7

Cost reduction and other expenses(3)

2.4

5.9

12.4

9.0

Non-cash share based expense

4.8

3.8

15.9

12.5

Other (income) expense, net adjustment(4)

(0.7)

0.1

12.1

9.3

Adjusted EBITDA

$          77.0

$          37.0

$        200.7

$        185.5

(1) Included in other (expense), net on the consolidated statements of income (loss).

(2) Included in selling, general and administrative expenses and other (expense), net within the consolidated statements of income (loss).  For the nine months ended September 30, 2024, certain legal matters include a net gain of $14.9 million related to a favorable judgment received in a Brazilian services tax matter.

(3) Reduced for depreciation and amortization included above.

(4) Other expense, net as reported on the consolidated statements of income (loss) less pension and postretirement expense, interest income and items included in certain legal and environmental matters, cost reduction and other expenses.

 

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

Revenue

$   497.0

$   464.6

$  1,463.0

$  1,457.8

Net loss attributable to Unisys Corporation as a percentage of revenue

(12.5) %

(10.8) %

(15.3) %

(18.2) %

Non-GAAP net (loss) income attributable to Unisys Corporation as a percentage of revenue

(1.2) %

(4.8) %

0.5 %

0.4 %

Adjusted EBITDA as a percentage of revenue

15.5 %

8.0 %

13.7 %

12.7 %

 

UNISYS CORPORATION

RECONCILIATIONS OF GAAP TO NON-GAAP

 (Unaudited)

(Millions)

OPERATING PROFIT(LOSS)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

Operating profit (loss)

$       7.5

$   (17.1)

$     48.8

$     32.9

Goodwill impairment

39.1

—

39.1

—

Certain legal matters(1)

(2.2)

9.3

8.2

23.7

Cost reduction and other expenses(2)

4.6

7.8

15.9

19.1

Pension and postretirement expense(1)

0.4

0.4

1.1

1.1

Non-GAAP operating profit

$     49.4

$       0.4

$   113.1

$     76.8

Revenue

$   497.0

$   464.6

$  1,463.0

$  1,457.8

Operating profit (loss) percent

1.5 %

(3.7) %

3.3 %

2.3 %

Non-GAAP operating profit percent

9.9 %

0.1 %

7.7 %

5.3 %

(1) Included in selling, general and administrative on the consolidated statements of income (loss).

(2) Included in cost of revenue, selling, general and administrative and research and development on the consolidated statements of income (loss).

 

EXCLUDING LICENSE AND SUPPORT (EX-L&S) REVENUE AND GROSS PROFIT

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

Revenue

$    497.0

$    464.6

$ 1,463.0

$ 1,457.8

L&S revenue

104.5

67.1

279.8

284.8

Ex-L&S Non-GAAP revenue

$    392.5

$    397.5

$ 1,183.2

$ 1,173.0

Gross profit

$    145.0

$      95.3

$     410.9

$    370.1

L&S gross profit

74.7

39.6

195.2

198.5

Ex-L&S Non-GAAP gross profit

$      70.3

$      55.7

$     215.7

$    171.6

Gross profit percent

29.2 %

20.5 %

28.1 %

25.4 %

Ex-L&S Non-GAAP gross profit percent

17.9 %

14.0 %

18.2 %

14.6 %

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/unisys-announces-3q24-results-302290589.html

SOURCE Unisys Corporation

Continue Reading

Technology

Kidney Patients Back Bipartisan Bill to Expand Disability Employment

Published

on

By

U.S. Representatives Hoyer and Sessions Lead AbilityOne Modernization Bill

Kidney Disease and Jobs are Focus of National Disability Employment Month

WASHINGTON, Oct. 23, 2026 /PRNewswire/ — The American Association of Kidney Patients (AAKP), the nation’s oldest and largest independent kidney patient advocacy organization, today announced plans to accelerate national grassroots patient advocacy in support of bipartisan legislation that will modernize the federal AbilityOne program. The American Procurement Improvement Act (APIA), H.R. 10443, is championed by U.S. Representatives Pete Sessions (R-TX) and Steny Hoyer (D-MD). AAKP defines kidney disease as both an American healthcare and workforce issue and fights to expand career opportunities and job protections for all Americans impacted by kidney disease, disabilities, and chronic diseases.

The AbilityOne program creates private sector employment opportunities for over 41,000 Americans with severe vision and other disabilities, including nearly 3,000 American Veterans. In FY 2025, the program generated nearly 48 million direct labor hours, an 8 percent increase and a significant measure of disability employment growth, with workers working and working more hours. AbilityOne delivered more than $4.7 billion in products and services to the Federal government in FY 2025 and drew discouraged workers into the U.S. labor force while supporting greater workforce participation, increasing economic independence, and self-sufficiency. The AbilityOne mission taps the underutilized workforce of people with significant disabilities to deliver high-quality, mission-essential products and services to federal agencies, including the U.S. Department of Defense and the U.S. Department of Homeland Security.

The APIA legislation removes outdated statutory barriers to hiring, retention, advancement, and movement into careers of choice, including emerging fields and new lines of business. It also modernizes federal procurement by aligning AbilityOne with contemporary procurement practices and streamlines procurement processes so the program can respond faster to emerging federal agency priorities. The APIA legislation protects taxpayer interests, strengthens program accountability and stewardship by preserving oversight, transparency, and worker protections while modernizing AbilityOne Commission authorities. The legislation is seen as an opportunity to improve federal procurement and strengthen the federal government’s domestic supplier base.

Over 36 million Americans live with kidney disease, over 600,000 are on dialysis, and nearly 100,000 are awaiting a kidney transplant. Further, interrelated cardiovascular, kidney, and metabolic diseases have impacted more than 25% of the adult population and are a leading cause of death. More broadly, the American Heart Association estimates that 90% of U.S. adults, or about 240 million people, have some degree of interconnected cardiovascular, kidney, or metabolic health conditions. For kidney patients dependent upon status-quo, in-center hemodialysis, burdensome thrice-weekly dialysis sessions force many patients, against their own choosing, into unemployment, disability, and dependency. AAKP believes dialysis-related unemployment, and the associated costs borne by families and taxpayers, is one of the media’s least-reported stories in legacy kidney care. AAKP’s policy agenda focuses on transplant readiness, more opportunities for organ transplants, more flexible, patient-centered home dialysis solutions, and stronger job protections for both kidney patients and living organ donors.

AAKP President Edward V. Hickey, III, a chronic kidney disease patient, stated, “AAKP strongly endorses the American Procurement Improvement Act (APIA) and expresses our deepest gratitude to Representatives Steny Hoyer and Peter Sessions for their bipartisan leadership and commitment to Americans managing disabilities and their efforts to secure meaningful employment opportunities with solid wages. People impacted by disability and chronic diseases face tremendous hurdles to continued employment and return to the workforce – especially America’s proud Veterans. This legislation reflects consensus language among stakeholders, including advocates, employers, and organized labor, and sends a very positive message, amid national economic concerns, that the voices and needs of disabled Americans and their families are heard and not forgotten by the U.S. Congress. We encourage Congress to step up and pass this legislation before the close of the year.” Hickey is a U.S. Marine Corps Veteran, a former senior congressional aide, and has served in appointed roles in two presidential administrations, including the U.S. Department of Commerce (DOC) and the U.S. Office of Personnel Management (OPM). At OPM, he was heavily involved in policy issues related to federal Veterans preference in civil service hiring and expanded federal job opportunities. He currently serves on the American Board of Internal Medicine’s (ABIM) Nephrology Specialty Board and as the Chair of the AAKP Veterans Health Initiative, the largest kidney health outreach program outside of the U.S. Department of Veterans Affairs.

October is National Disability Employment Month, and AAKP and its allies remind elected and appointed government leaders to address health and employment concerns that impact patients, families, and communities. Through multiple partnerships, AAKP leads the kidney community in providing kidney patients and transplant recipients, including Veterans, access to virtual job fairs and employment skills training opportunities. AAKP is currently sponsoring virtual job fairs, in partnership with CareerEco, on January 13, 2027, and May 18, 2027, that will service Veterans and military families. AAKP’s past collaborations have included webinars with Idealist and virtual disability and Veteran hiring fairs with Bender Consulting.

AAKP Vice President and Chair of Policy and Global Affairs Paul T. Conway, a 49-year kidney patient and 29-year transplant recipient, stated, “The AbilityOne program has supported private sector employment for people managing disabilities and chronic diseases for nearly ninety years and reflects the exceptional American values of self-reliance and independence. Representatives Steny Hoyer and Pete Sessions have consistently shown respect for the creativity, talents, and skills of disabled citizens and have dedicated their public careers to expanding job opportunities in the workforce and across the federal supply chain. The American Procurement Improvement Act increases accountability for taxpayer funds and will result in more well-paying jobs for Americans whose desire and capacity to work and contribute are underappreciated.” Conway is a former Chief of Staff for both the U.S. Department of Labor and the U.S. Office of Personnel Management and a former Deputy Secretary for Health and Human Resources for the Commonwealth of Virginia. He has overseen multiple federal and state disability employment, workforce training, and health service programs throughout his public career. He is the past Chair of the U.S. Food and Drug Administration’s Patient Engagement Advisory Committee (PEAC) and serves on the Observational Study Monitoring Board of the Kidney Precision Medicine Program (KPMP) administered by the National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases (NIH/NIDDK).

To advance the APIA, AAKP is working with former U.S. Representative Tony Coelho, Chair of the Partnership to Improve Patient Care as well as the Alliance for Expanding America’s Workforce. Along with AAKP, APIA is endorsed by over 60 national patient and disability organizations, labor unions and employers including the American Association of People with Disabilities, SEIU, Bender Consulting, National Council of SourceAmerica Employers, CEO Commission for Disability Employment, the Arc of the United States, National Organization on Disability, National Down Syndrome Society, National Disability Rights Network, National Federation of the Blind, Melwood Inc., WORK Inc., ORC Industries, Employment Source, Opportunity Center, Inc., PARC, ACHIEVE Human Services, Inc., Human Technologies, InspiriTec, PORTCO Inc, PRIDE Industries, Phoenix, Pueblo Diversified Industries, and the Association of People Supporting EmploymentFirst (APSE).

AAKP, alongside a broad and diverse coalition of patient organizations, transplant experts, and Congressional allies, is also working to secure passage of the Living Donor Protection Act (LDPA), S. 1552/H.R. 4582 and H.R. 4583, in 2026. The bipartisan bill protects living organ donors from job and insurance discrimination based solely on their decision to donate a kidney to save another life, barriers cited most often by potential organ donors. The bipartisan legislation is led by Senator Tom Cotton (R-AK) and Senator Kirsten Gillibrand (D-NY). It was voted out of the Senate HELP Committee on February 26, 2026, with full bipartisan support, the endorsement of AAKP, the larger kidney community, and the American Council of Life Insurance (ACLI).

In 2018, with bipartisan support from Congress and the Trump Administration, AAKP and transplant professionals worked with the U.S. Department of Labor’s (DOL) legal team and the DOL Wage and Hour Division to have DOL issue Family and Medical Leave Act (FMLA) protections for living organ donors, based on the original intent of the FMLA’s Congressional co-sponsors (click here to read the letter and click here to watch the video). Congressional passage of the LDPA in 2026 will codify the DOL’s 2018 FMLA job protections and prohibit insurers from discriminating against living donors. Increased living organ donation, improved transplant readiness among kidney patients, and greater opportunities for transplantation have been national goals for decades and were reinforced in 2019 through the Executive Order on Advancing American Kidney Health.

Follow AAKP on social media at @kidneypatient on Facebook, @kidneypatients on X, and @kidneypatients on Instagram, and visit https://aakp.org/ for more information. AAKP patient advocates advance bipartisan kidney policy including: passage of the bipartisan law modernizing the Organ Procurement and Transplantation Network (OPTN) (2023); lifetime transplant drug coverage for kidney patients (2020); the historic Executive Order on Advancing American Kidney Health signed by President Donald Trump (2019); job protections for living organ donors under the Family Medical Leave Act (FMLA) via the U.S. Department of Labor (2018); and Congressional approval of HIV positive organ transplants for HIV positive patients (2013).

MEDIA CONTACT:
Brendan LaCivita
National and Medical Media Specialist
blacivita@aakp.org
(813) 906-7740

View original content to download multimedia:https://www.prnewswire.com/news-releases/kidney-patients-back-bipartisan-bill-to-expand-disability-employment-302918393.html

SOURCE American Association of Kidney Patients

Continue Reading

Technology

BioVid Launches Mimetics™, AI Research Audiences Built on How Physicians Reason and Decide

Published

on

By

Modeling physician response patterns and behavior, showing an 80–90% match with real physicians on content, reasoning, and emotion. 

BRISTOL, Pa., Oct. 23, 2026 /PRNewswire/ — BioVid, a life science consultancy, today announced the launch of BioVid Mimetics™, a research platform that gives pharmaceutical teams mimetics: synthetic physician audiences modeled on how those audiences reason and decide. Its respondent models are grounded in BioVid’s proprietary MindSet Modeling™ program, large-scale, multi-specialty surveys of practicing physicians that measure the mindsets shaping how they process information, make judgments, and decide. The models are aligned with secondary data on clinical practice, moving beyond generic AI role-play to model the decision logic behind treatment choices.

Like a mimetic drug, each BioVid mimetic is tested against the original: real physicians.

Prescribing data shows what physicians choose, not why. Pharma teams now face more of those “why” questions than research budgets and timelines can absorb. BioVid Mimetics™ applies the social and behavioral science of clinical judgment to model how physicians interpret evidence, weigh benefit against risk, and decide when they know enough to act.

The name comes from pharmacology, where a mimetic earns trust by doing the work of the original molecule. Every BioVid mimetic is tested against that standard, bringing the firm’s long-standing commitment to science-based research to a new method.

“At BioVid, we’ve always believed that better commercial decisions start with a deeper understanding of human behavior,” said Peggy Hirtle, CEO of BioVid. “Our goal was never simply faster or cheaper respondents. It was to reflect how physicians actually reason, with the same scientific rigor clients already trust from BioVid. Mimetics is a new way to put human understanding to work, never a replacement for it.”

“A synthetic respondent can sound right and still reason wrong. The real test is whether it reasons the way the audience does,” said Marco Barcella, Executive Director, Product & Technology at BioVid. “Where the decision warrants, we run the same study with a human cohort and a mimetic cohort and compare the findings, the reasoning, and the mental and emotional responses directly. Clients see where mimetic findings hold and where human research should lead.”

In BioVid’s validation work to date, mimetic and human cohorts have shown an 80% to 90% match on content, reasoning, and emotion across thousands of parallel tests.

BioVid Mimetics™ is available off the shelf or tailored with a client’s own primary research. It supports message and concept testing, positioning, drivers and barriers, segmentation, and opportunity assessment, and includes:

Mimetic Respondents: Mimetic or hybrid studies, with mimetic fieldwork complete in one to two weeks after receipt of required inputs, followed by a full report and readout from BioVid’s research team.

Mimetic Segments App: Segments that client teams question directly, share materials with, and return to between research waves.

Client Customization: Models tailored with a client’s own research, segment profiles, and CRM data, exclusive to that client and firewalled from all others.

To learn more, visit www.biovid.com/mimetics. 

About BioVid

BioVid is a life science consultancy applying behavioral science and AI to commercial and market access strategy. Its offerings include the CIAIRA™ AI platform, Tumor Worlds™, and BioVid Mimetics™. BioVid is a recognized leader in new product demand estimation, commercial communication optimization, and customer and patient segmentation research.

Visit www.biovid.com.

Media Contact:
Sal Zerilli, PhD, Executive Director, Knowledge and Innovation, BioVid
szerilli@biovid.com | 267.201.4008

View original content to download multimedia:https://www.prnewswire.com/news-releases/biovid-launches-mimetics-ai-research-audiences-built-on-how-physicians-reason-and-decide-302918401.html

SOURCE BioVid

Continue Reading

Technology

Egan-Jones Finds Steady CLO Credit Metrics as Interest Rates Turn Higher

Published

on

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Egan-Jones released its monthly report on the collateralized loan obligation (CLO) market, finding that credit metrics across the deals it rates held steady even as interest rates and high-yield spreads moved higher in September. For investors, the publication sets these steadier portfolio measures against a tighter rate backdrop.

Among Egan-Jones’ measures, the weighted average rating score, a gauge of the default risk in a deal’s underlying loans where a lower score indicates stronger credit, has improved over the past year. The share of assets rated CCC+ or lower, the weakest tier of loan ratings, has been stable to slightly lower, with a median of 6.1%. As of September 2026, Egan-Jones rated 1,568 CLO deals.

The steadier metrics come as financing conditions shift. The 5-year Treasury yield rose 60 basis points to 5.09%, its highest close of 2026, and on September 16 the Federal Reserve raised rates by 25 basis points, its first increase since 2023. High-yield spreads widened to 312 basis points from their late-August low, while new CLO issuance totaled 91 deals ($38.2 billion), down 12.5% by count from a year earlier.

Higher rates cut both ways for CLOs, according to the analysis: coupons on the underlying loans reset upward, but so do the interest burdens of the borrowers. Egan-Jones points to rising loss severity on distressed exchanges and other selective defaults, and identifies software loans, pressured by concerns over disruption from artificial intelligence, as the weakest sector in CLO portfolios.

Egan-Jones also compares its ratings with those of other agencies across 20 deals, ranking the tranches where views differ most. On that comparison, Egan-Jones currently tends to take a more positive view of CLO credit quality than other credit rating agencies. A full sample rating report on MP CLO VIII, whose largest industry exposure is High Tech Industries at 15.9%, is included.

Taken together, the findings describe a market in which issuance has eased and borrowing costs are rising, while the credit profile of Egan-Jones-rated portfolios remains stable. Watching where pressures such as software exposure and loss severity are building may help investors assess CLO risk as the rate cycle turns.

About Egan-Jones Ratings
Egan-Jones, an NRSRO founded in 1995, offers timely and accurate credit ratings and proxy services.

Media Contact:
sales@egan-jones.com
+1 212 425 0460

View original content to download multimedia:https://www.prnewswire.com/news-releases/egan-jones-finds-steady-clo-credit-metrics-as-interest-rates-turn-higher-302918341.html

SOURCE Egan-Jones Ratings Co.

Continue Reading

Trending